Outcomes in liver transplant recipients
โ
Guy W. Neff; Christopher B. O'Brien; Jose Nery; Norah Shire; Marzia Montalbano;
๐
Article
๐
2004
๐
John Wiley and Sons
๐
English
โ 125 KB
Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents. T